Bank Julius Baer & Co
NVCR icon

Bank Julius Baer & Co’s NovoCure NVCR Stock Holding History

Bank Julius Baer & Co’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$15K – 731
2021
Q4 		$15K Buy
200
+50
+33% +$5.02K ﹤0.01% 766
2021
Q3 		$17K Buy
150
+1
+0.7% +$151 ﹤0.01% 753
2021
Q2 		$33K Sell
149
-1
-0.7% -$195 ﹤0.01% 719
2021
Q1 		$20K Buy
+150
New +$23.7K ﹤0.01% 746
2020
Q2 		– Sell
-104
Closed -$7K – 721
2020
Q1 		$7K Buy
+104
New +$8.22K ﹤0.01% 614

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co's NVCR Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 200 shares — an estimated $15K sold.

Bank Julius Baer & Co first reported a position in NVCR in Q1 2020 and held it in 5 quarters. The position peaked at $33K in Q2 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 200 NovoCure shares in Q1 2022, an estimated $15K.
  • Bank Julius Baer & Co first reported a position in NovoCure in Q1 2020 and held it in 5 quarters.
  • Bank Julius Baer & Co's NovoCure position peaked at $33K in Q2 2021.
  • 308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.